Format

Send to

Choose Destination
Z Rheumatol. 2014 Dec;73(10):897-906. doi: 10.1007/s00393-014-1397-9.

[Current news from the BIKER register].

[Article in German]

Author information

1
Kinderrheumazentrum Sankt Augustin, Zentrum für Allgemeine Pädiatrie und Neonatologie, Asklepios Klinik, Arnold-Janssen Str. 29, 53757, Sankt Augustin, Deutschland, g.horneff@asklepios.com.

Abstract

Innovative developments in the pharmacotherapy of juvenile idiopathic arthritis and especially biologics allow the formulation of new therapeutic targets, such as the rapid induction of remission with shortening of the period of active disease and therefore preventing damage and disability. These new therapies also represent a challenge to the monitoring of drug safety, the pharmacovigilance. For this purpose the Society for Paediatric and Adolescent Rheumatology has set up an early register to record achievements in treatment improvement and in addition to independently assess information on drug safety, acute tolerance and long-term safety.

PMID:
25269873
DOI:
10.1007/s00393-014-1397-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center